Top News: #ProstateCancer

Here are the top read news for #ProstateCancer:

prostatecancertherapy-650x450Common Prostate Cancer Therapy Linked to Increased Risk of Dementia:

The study, conducted by researchers at the University of Pennsylvania, showed an association between the use of androgen deprivation therapy (ADT) and increased risk of dementia. The researchers studied electronic medical records of more than 9,000 men diagnosed with prostate cancer and looked to see who was diagnosed with dementia during follow-up. Men who had been on ADT for at least a year had a higher likelihood of developing dementia, as did men who started ADT after age 70. ADT also has been associated with metabolic syndrome, which raises the risk of heart disease, diabetes and stroke.: Read more


crawford_davidProstate cancer patients more likely to die of other diseases, say 15-year PLCO results:

Fifteen-year follow-up results focusing on prostate cancer were published this month in the journal Cancer, and show little difference in mortality between men screened annually and the control group, some of whom chose to be screened occasionally. According to researchers, the results don’t necessarily negate the value of prostate cancer screening, but imply that within the data of this massive trial are clues that inform personalized decisions for subsets of this prostate cancer population: Read more


goldsteinandrew_thmbNew evidence links inflammation and increased prostate cancer risk:

UCLA researchers have discovered a previously unrecognized type of progenitor cell that, though rare in most regions of the human prostate, is found in uncommonly high numbers in inflamed areas of the gland. These progenitor cells have the ability to initiate prostate cancer in response to genetic changes. The study results suggest inflammation increases overall risk for the disease by increasing the available pool of progenitor cells that can develop into prostate cancer: Read more


191216_mainLight therapy effectively treats early prostate cancer:

The new treatment, ‘vascular-targeted photodynamic therapy’ (VTP), involves injecting a light-sensitive drug into the bloodstream and then activating it with a laser to destroy tumour tissue in the prostate. The research, published in The Lancet Oncology, found that around half (49%) of patients treated with VTP went into complete remission compared with 13.5% in the control group. “These results are excellent news for men with early localised prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,” says Professor Emberton: Read more


makingsoundwMaking (sound) waves in the fight against cancer:

“Currently the best way to get information is through a biopsy, which involves pushing 12 needles through an organ the size of a walnut. As you might imagine, it’s a very uncomfortable and invasive procedure,” says Lewis, the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta and a member of the Cancer Research Institute of Northern Alberta. “Patients with low grade prostate cancer can decide not to get treatment and instead monitor the disease, but monitoring usually involves a biopsy every year or so. Many people opt for surgery instead of more biopsies. It is clearly something we need to improve upon”: Read more